triamcinolone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
steroids not used as glucocorticosteroids 2725 124-94-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • triamcinolone
  • triamcinlon
  • triamcinolon
  • rodinolone
A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739)
  • Molecular weight: 394.44
  • Formula: C21H27FO6
  • CLOGP: 0.71
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 4
  • TPSA: 115.06
  • ALOGS: -2.67
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
7.50 mg O
7.50 mg P
0.22 mg N

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.08 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 23 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 3, 1957 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Adrenal insufficiency 417.79 11.43 182 24833 12942 46648105
Psoriasis 322.63 11.43 295 24720 78309 46582738
Body height below normal 255.36 11.43 76 24939 1763 46659284
Human antichimeric antibody positive 235.00 11.43 67 24948 1329 46659718
Juvenile idiopathic arthritis 181.01 11.43 72 24943 4060 46656987
Bone density decreased 157.43 11.43 85 24930 9667 46651380
Obesity 147.53 11.43 93 24922 14113 46646934
Polyarthritis 137.22 11.43 68 24947 6474 46654573
Non-infectious endophthalmitis 132.14 11.43 29 24986 181 46660866
Hypothalamic pituitary adrenal axis suppression 127.42 11.43 27 24988 139 46660908
Drug specific antibody 119.91 11.43 39 24976 1221 46659826
Skin atrophy 118.69 11.43 54 24961 4246 46656801
Joint destruction 108.99 11.43 46 24969 3018 46658029
Adrenal suppression 105.16 11.43 33 24982 918 46660129
Wheelchair user 103.32 11.43 48 24967 3960 46657087
Antibody test positive 88.85 11.43 36 24979 2129 46658918
Intraocular pressure increased 85.34 11.43 48 24967 5909 46655138
Eye infection toxoplasmal 81.63 11.43 21 24994 277 46660770
Retinal artery occlusion 77.72 11.43 29 24986 1373 46659674
Ocular hypertension 77.28 11.43 25 24990 769 46660278
Necrotising scleritis 76.94 11.43 18 24997 155 46660892
Cushingoid 70.04 11.43 43 24972 6223 46654824
Injection site atrophy 69.16 11.43 21 24994 522 46660525
Cushing's syndrome 65.60 11.43 22 24993 759 46660288
Completed suicide 65.52 11.43 3 25012 145917 46515130
Red blood cell sedimentation rate increased 64.26 11.43 70 24945 22819 46638228
Secondary adrenocortical insufficiency 63.15 11.43 22 24993 853 46660194
Septic shock 60.39 11.43 110 24905 57783 46603264
Tractional retinal detachment 60.14 11.43 12 25003 43 46661004
Rhegmatogenous retinal detachment 60.10 11.43 13 25002 75 46660972
Mycotic endophthalmitis 58.83 11.43 11 25004 25 46661022
Chorioretinopathy 58.79 11.43 20 24995 721 46660326
Synovitis 56.20 11.43 110 24905 60965 46600082
Toxicity to various agents 52.35 11.43 24 24991 211742 46449305
Retinal pigment epithelial tear 51.62 11.43 14 25001 229 46660818
Therapy non-responder 45.22 11.43 80 24935 41072 46619975
Visual acuity reduced 44.43 11.43 57 24958 22056 46638991
Bursitis infective 42.96 11.43 18 24997 1159 46659888
Steroid withdrawal syndrome 41.91 11.43 14 25001 477 46660570
Arthritis 40.92 11.43 112 24903 77204 46583843
Macular oedema 40.45 11.43 26 24989 4075 46656972
Keratitis fungal 40.13 11.43 10 25005 115 46660932
Intentional product use issue 39.12 11.43 87 24928 52693 46608354
Immunodeficiency 38.39 11.43 41 24974 13065 46647982
Dermatitis contact 38.22 11.43 33 24982 8090 46652957
Perioral dermatitis 37.82 11.43 9 25006 84 46660963
Macular degeneration 37.45 11.43 31 24984 7174 46653873
Mobility decreased 37.41 11.43 93 24922 60501 46600546
Gastroenteritis viral 36.86 11.43 47 24968 18072 46642975
Pyloric abscess 36.76 11.43 6 25009 3 46661044
Rapidly progressive osteoarthritis 35.04 11.43 6 25009 6 46661041
C-reactive protein increased 34.16 11.43 88 24927 58502 46602545
Lipoatrophy 34.07 11.43 11 25004 336 46660711
Endophthalmitis 32.87 11.43 21 24994 3257 46657790
Quality of life decreased 32.74 11.43 26 24989 5676 46655371
Death 30.55 11.43 86 24929 335462 46325585
Human anti-human antibody test 29.90 11.43 10 25005 342 46660705
Retinitis viral 29.20 11.43 5 25010 5 46661042
Retinal artery embolism 28.71 11.43 7 25008 73 46660974
Tendon rupture 27.68 11.43 27 24988 7732 46653315
Conjunctival ulcer 26.87 11.43 6 25009 41 46661006
Diarrhoea 26.70 11.43 434 24581 559168 46101879
Dystrophic calcification 26.44 11.43 7 25008 104 46660943
Soft tissue atrophy 26.13 11.43 4 25011 0 46661047
Type I hypersensitivity 25.96 11.43 16 24999 2330 46658717
Extraskeletal ossification 25.71 11.43 6 25009 51 46660996
Product contamination 25.63 11.43 10 25005 535 46660512
Product use in unapproved indication 24.82 11.43 105 24910 90168 46570879
Condition aggravated 24.49 11.43 219 24796 244833 46416214
Rash 24.44 11.43 295 24720 356217 46304830
Articular calcification 24.32 11.43 6 25009 66 46660981
Orbital infection 23.89 11.43 5 25010 24 46661023
Drug abuse 23.71 11.43 3 25012 63405 46597642
Necrotising retinitis 23.61 11.43 8 25007 285 46660762
Spinal cord infarction 23.53 11.43 8 25007 288 46660759
Uveitis 23.50 11.43 26 24989 8615 46652432
Scleral thinning 22.95 11.43 5 25010 30 46661017
Birdshot chorioretinopathy 22.93 11.43 6 25009 85 46660962
Cutaneous nocardiosis 22.47 11.43 4 25011 6 46661041
Alopecia universalis 22.42 11.43 6 25009 93 46660954
Polypoidal choroidal vasculopathy 22.19 11.43 6 25009 97 46660950
Intentional overdose 22.16 11.43 4 25011 64940 46596107
Product dose omission issue 21.93 11.43 160 24855 168360 46492687
Necrotising fasciitis 21.93 11.43 15 25000 2608 46658439
Plastic surgery 21.91 11.43 6 25009 102 46660945
Acanthosis 21.43 11.43 6 25009 111 46660936
Retinal haemorrhage 21.29 11.43 19 24996 4864 46656183
Macular fibrosis 21.17 11.43 8 25007 392 46660655
Skin odour abnormal 21.11 11.43 12 25003 1507 46659540
Purpura senile 20.82 11.43 9 25006 626 46660421
Cataract subcapsular 20.77 11.43 9 25006 630 46660417
General physical health deterioration 20.59 11.43 19 24996 115750 46545297
Vitreous opacities 20.53 11.43 7 25008 254 46660793
Infusion related reaction 19.98 11.43 15 25000 101193 46559854
Hypocalcaemia 19.66 11.43 44 24971 26741 46634306
Exposure via breast milk 19.65 11.43 11 25004 1341 46659706
Extradural abscess 19.58 11.43 9 25006 724 46660323
Choroiditis 19.39 11.43 6 25009 159 46660888
Iridoschisis 19.32 11.43 4 25011 18 46661029
Parakeratosis 19.25 11.43 6 25009 163 46660884
Shared psychotic disorder 19.14 11.43 4 25011 19 46661028
Impaired quality of life 19.08 11.43 15 25000 3227 46657820
Coma 19.05 11.43 4 25011 58345 46602702
Dermatophytosis 18.95 11.43 6 25009 172 46660875
Detachment of retinal pigment epithelium 18.43 11.43 7 25008 348 46660699
Abscess neck 18.36 11.43 8 25007 567 46660480
Malignant neoplasm progression 18.26 11.43 6 25009 64920 46596127
Bone density increased 18.26 11.43 7 25008 357 46660690
Blindness 18.23 11.43 33 24982 17236 46643811
Staphylococcal infection 18.10 11.43 51 24964 35720 46625327
Skin discolouration 17.93 11.43 48 24967 32632 46628415
Soft tissue swelling 17.84 11.43 9 25006 889 46660158
Loss of personal independence in daily activities 17.68 11.43 69 24946 57114 46603933
Cataract 17.61 11.43 59 24956 45356 46615691
Infective scleritis 17.52 11.43 3 25012 3 46661044
Optic nerve cupping 17.52 11.43 3 25012 3 46661044
Age-related macular degeneration 17.52 11.43 8 25007 634 46660413
Product contamination microbial 17.46 11.43 6 25009 223 46660824
Tarsal tunnel syndrome 17.36 11.43 8 25007 647 46660400
Eye infection fungal 17.35 11.43 5 25010 103 46660944
Bradycardia 17.17 11.43 7 25008 66291 46594756
Acute kidney injury 16.93 11.43 67 24948 235788 46425259
Neutropenia 16.79 11.43 32 24983 143172 46517875
Eczema 16.68 11.43 35 24980 20365 46640682
Retinal exudates 16.62 11.43 8 25007 714 46660333
Psoriatic arthropathy 16.61 11.43 50 24965 36329 46624718
Panophthalmitis 16.38 11.43 4 25011 42 46661005
Peripheral vascular disorder 16.28 11.43 18 24997 5959 46655088
Application site pain 16.26 11.43 15 25000 4008 46657039
Dermatitis 16.09 11.43 28 24987 14180 46646867
Depressed level of consciousness 16.08 11.43 3 25012 47566 46613481
Conjunctival haemorrhage 15.86 11.43 13 25002 2968 46658079
Electrocardiogram QT prolonged 15.80 11.43 4 25011 51321 46609726
Retinal degeneration 15.66 11.43 7 25008 528 46660519
Drug specific antibody present 15.65 11.43 13 25002 3023 46658024
Hyperadrenocorticism 15.54 11.43 6 25009 312 46660735
Alkalosis 15.52 11.43 6 25009 313 46660734
Pruritus 15.47 11.43 198 24817 242154 46418893
Deposit eye 15.44 11.43 3 25012 9 46661038
Mucocutaneous ulceration 15.24 11.43 5 25010 161 46660886
Arthritis bacterial 15.15 11.43 17 24998 5719 46655328
Hidradenitis 15.14 11.43 11 25004 2104 46658943
Chorioretinal folds 14.98 11.43 3 25012 11 46661036
Night blindness 14.95 11.43 6 25009 346 46660701
Overdose 14.56 11.43 20 24995 101959 46559088
Short stature 14.27 11.43 5 25010 197 46660850
Arthritis fungal 14.23 11.43 3 25012 15 46661032
Hirsutism 14.21 11.43 8 25007 986 46660061
Retinal vasculitis 14.13 11.43 7 25008 665 46660382
Prescribed underdose 13.97 11.43 24 24991 12029 46649018
Diabetic ulcer 13.83 11.43 5 25010 216 46660831
Maternal exposure during pregnancy 13.77 11.43 21 24994 102528 46558519
Eye abscess 13.59 11.43 4 25011 89 46660958
Autoimmune colitis 13.43 11.43 6 25009 452 46660595
Rhabdomyolysis 13.42 11.43 3 25012 41906 46619141
Resorption bone increased 13.28 11.43 8 25007 1119 46659928
Skin plaque 13.25 11.43 16 24999 5819 46655228
Drug ineffective for unapproved indication 13.23 11.43 28 24987 16385 46644662
Chorea 13.19 11.43 8 25007 1132 46659915
Complex regional pain syndrome 13.12 11.43 10 25005 2056 46658991
Dry skin 13.09 11.43 50 24965 40966 46620081
Pseudoendophthalmitis 13.02 11.43 3 25012 24 46661023
Cardio-respiratory arrest 12.98 11.43 8 25007 59861 46601186
Wound secretion 12.91 11.43 13 25002 3867 46657180
Corneal oedema 12.79 11.43 9 25006 1637 46659410
Joint effusion 12.76 11.43 23 24992 11972 46649075
Glossodynia 12.65 11.43 4 25011 44369 46616678
Syncope 12.65 11.43 23 24992 104780 46556267
Cardiac arrest 12.64 11.43 18 24997 90381 46570666
Posterior capsule opacification 12.43 11.43 4 25011 121 46660926
Keratopathy 12.25 11.43 5 25010 301 46660746
Macular ischaemia 12.16 11.43 3 25012 33 46661014
Hypoglycaemia 12.15 11.43 7 25008 54342 46606705
Retinal ischaemia 12.07 11.43 5 25010 313 46660734
Spinal cord ischaemia 12.00 11.43 3 25012 35 46661012
Blood creatinine increased 11.93 11.43 14 25001 76389 46584658
Vestibular disorder 11.87 11.43 8 25007 1358 46659689
Rash pruritic 11.81 11.43 51 24964 44164 46616883
Retinal detachment 11.61 11.43 14 25001 5086 46655961
Retinal scar 11.61 11.43 4 25011 150 46660897
Hyponatraemia 11.56 11.43 23 24992 101309 46559738
Skin hypopigmentation 11.47 11.43 5 25010 355 46660692

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 219.26 13.07 169 13302 42337 29896670
Non-infectious endophthalmitis 165.28 13.07 33 13438 148 29938859
Visual acuity reduced 158.47 13.07 95 13376 15751 29923256
Ocular hypertension 141.02 13.07 38 13433 730 29938277
Endophthalmitis 111.15 13.07 46 13425 3434 29935573
Mycotic endophthalmitis 106.93 13.07 19 13452 37 29938970
Eye infection toxoplasmal 98.99 13.07 22 13449 179 29938828
Chorioretinopathy 93.23 13.07 32 13439 1420 29937587
Adrenal suppression 91.69 13.07 26 13445 607 29938400
Intraocular pressure increased 88.17 13.07 44 13427 5076 29933931
Deposit eye 83.25 13.07 14 13457 16 29938991
Hypothalamic pituitary adrenal axis suppression 81.44 13.07 19 13452 196 29938811
Rash 70.03 13.07 217 13254 191672 29747335
Glaucoma 68.47 13.07 39 13432 5869 29933138
Infective scleritis 67.78 13.07 11 13460 8 29938999
Retinal artery occlusion 59.72 13.07 24 13447 1660 29937347
Macular oedema 57.62 13.07 27 13444 2711 29936296
Product compounding quality issue 56.10 13.07 10 13461 20 29938987
Cystoid macular oedema 55.54 13.07 18 13453 667 29938340
Necrotising retinitis 50.55 13.07 17 13454 708 29938299
Adrenal insufficiency 48.23 13.07 39 13432 10424 29928583
Steroid withdrawal syndrome 45.52 13.07 12 13459 211 29938796
Retinal artery embolism 45.32 13.07 9 13462 39 29938968
Uveitis 45.00 13.07 29 13442 5448 29933559
Retinal detachment 44.58 13.07 28 13443 5032 29933975
Retinal oedema 43.45 13.07 14 13457 509 29938498
Macular fibrosis 42.99 13.07 13 13458 382 29938625
Visual field defect 42.77 13.07 26 13445 4410 29934597
Product dose omission issue 42.39 13.07 113 13358 91518 29847489
Product contamination microbial 40.21 13.07 14 13457 648 29938359
Chondritis 39.61 13.07 10 13461 147 29938860
Retinal pigment epithelial tear 39.15 13.07 11 13460 248 29938759
Transmission of an infectious agent via product 38.93 13.07 10 13461 158 29938849
Retinal degeneration 38.82 13.07 11 13460 256 29938751
Diabetic retinal oedema 38.07 13.07 11 13460 275 29938732
Perioral dermatitis 37.49 13.07 9 13462 106 29938901
Pruritus 36.96 13.07 127 13344 118077 29820930
Retinal haemorrhage 36.24 13.07 24 13447 4719 29934288
Spinal cord infarction 35.91 13.07 10 13461 218 29938789
Toxicity to various agents 35.05 13.07 18 13453 177165 29761842
Eye pain 34.51 13.07 34 13437 11755 29927252
Intracranial hypotension 34.09 13.07 10 13461 264 29938743
Choroidal infarction 33.99 13.07 8 13463 86 29938921
Injection site plaque 33.54 13.07 5 13466 0 29939007
Application site pruritus 33.37 13.07 15 13456 1368 29937639
Maculopathy 32.57 13.07 13 13458 883 29938124
Cataract 31.85 13.07 44 13427 21791 29917216
Retinal scar 31.46 13.07 9 13462 217 29938790
Lenticular opacities 31.38 13.07 9 13462 219 29938788
Cytomegalovirus chorioretinitis 31.11 13.07 19 13452 3249 29935758
Rhegmatogenous retinal detachment 30.80 13.07 6 13465 23 29938984
Cushing's syndrome 28.95 13.07 10 13461 452 29938555
Symmetrical drug-related intertriginous and flexural exanthema 28.83 13.07 8 13463 172 29938835
Skin exfoliation 28.41 13.07 43 13428 23129 29915878
Injection site calcification 28.39 13.07 5 13466 9 29938998
Hyperadrenocorticism 28.11 13.07 7 13464 97 29938910
Shared psychotic disorder 26.87 13.07 5 13466 14 29938993
Injection site atrophy 26.76 13.07 6 13465 51 29938956
Cauda equina syndrome 26.44 13.07 9 13462 389 29938618
Dermatitis contact 26.27 13.07 17 13454 3214 29935793
Cataract subcapsular 26.14 13.07 8 13463 245 29938762
Eye abscess 25.16 13.07 7 13464 152 29938855
Drug ineffective 25.07 13.07 248 13223 340139 29598868
Skin hypopigmentation 24.59 13.07 8 13463 300 29938707
Polypoidal choroidal vasculopathy 24.39 13.07 8 13463 308 29938699
Anaphylactic reaction 23.70 13.07 44 13427 27938 29911069
Rash pruritic 23.67 13.07 39 13432 22533 29916474
Spondylitis 23.43 13.07 11 13460 1109 29937898
Intentional product use issue 23.33 13.07 51 13420 36389 29902618
Myoclonic epilepsy 23.30 13.07 10 13461 816 29938191
Choroiditis 23.20 13.07 10 13461 825 29938182
Subretinal fibrosis 23.06 13.07 6 13465 100 29938907
Blindness 22.94 13.07 28 13443 12281 29926726
Cerebral venous thrombosis 22.74 13.07 9 13462 598 29938409
Subretinal fluid 22.61 13.07 7 13464 223 29938784
Cushingoid 22.50 13.07 14 13457 2473 29936534
Mycobacterium kansasii infection 22.49 13.07 7 13464 227 29938780
Eczema 21.10 13.07 28 13443 13341 29925666
Open globe injury 21.05 13.07 4 13467 13 29938994
Retinal deposits 20.20 13.07 4 13467 17 29938990
Vitreous haemorrhage 19.40 13.07 12 13459 2098 29936909
Pain 19.15 13.07 138 13333 172503 29766504
Vitreous opacities 18.42 13.07 6 13465 226 29938781
Completed suicide 18.35 13.07 11 13460 99481 29839526
Periphlebitis 18.04 13.07 3 13468 3 29939004
Retinopathy proliferative 17.74 13.07 4 13467 35 29938972
Psoriatic arthropathy 17.57 13.07 28 13443 15733 29923274
Age-related macular degeneration 17.33 13.07 7 13464 490 29938517
Urticaria 17.31 13.07 59 13412 54547 29884460
Application site swelling 17.25 13.07 6 13465 277 29938730
Retinitis viral 16.83 13.07 3 13468 6 29939001
Eye inflammation 16.83 13.07 10 13461 1627 29937380
Drug abuse 16.71 13.07 8 13463 82064 29856943
Skin discolouration 16.17 13.07 27 13444 15767 29923240
Amblyopia 15.77 13.07 4 13467 60 29938947
Dermatitis allergic 15.70 13.07 16 13455 5756 29933251
Retinal disorder 15.56 13.07 8 13463 981 29938026
Macular hole 15.54 13.07 5 13466 181 29938826
Skin plaque 15.51 13.07 13 13458 3649 29935358
Eye infection syphilitic 15.30 13.07 3 13468 12 29938995
Retinal infarction 14.78 13.07 4 13467 78 29938929
General physical health deterioration 14.65 13.07 14 13457 99930 29839077
Dermatitis 14.33 13.07 18 13453 8124 29930883
Skin atrophy 14.21 13.07 9 13462 1639 29937368
Dry skin 13.88 13.07 31 13440 22423 29916584
Application site erythema 13.71 13.07 10 13461 2293 29936714
Surgery 13.54 13.07 21 13450 11530 29927477
Confusional state 13.54 13.07 25 13446 134809 29804198
Visual impairment 13.50 13.07 37 13434 30401 29908606
Product use in unapproved indication 13.34 13.07 67 13404 73626 29865381
Lens disorder 13.13 13.07 3 13468 28 29938979

Pharmacologic Action:

SourceCodeDescription
ATC A01AC01 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Corticosteroids for local oral treatment
ATC C05AA12 CARDIOVASCULAR SYSTEM
VASOPROTECTIVES
AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
Corticosteroids
ATC D07AB09 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, PLAIN
Corticosteroids, moderately potent (group II)
ATC D07XB02 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, OTHER COMBINATIONS
Corticosteroids, moderately potent, other combinations
ATC H02AB08 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
CORTICOSTEROIDS FOR SYSTEMIC USE
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
Glucocorticoids
ATC R01AD11 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Corticosteroids
ATC R03BA06 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
Glucocorticoids
ATC S01BA05 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFLAMMATORY AGENTS
Corticosteroids, plain
ATC D07BB03 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
Corticosteroids, moderately potent, combinations with antiseptics
ATC D07CB01 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
Corticosteroids, moderately potent, combinations with antibiotics
ATC S02CA04 SENSORY ORGANS
OTOLOGICALS
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
Corticosteroids and antiinfectives in combination
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:50857 anti-allergic agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Disorder of musculoskeletal system indication 928000 DOID:17
Cerebral edema indication 2032001
Lichen planus indication 4776004 DOID:9201
Berylliosis indication 8247009 DOID:10322
Psoriasis indication 9014002 DOID:8893
Ankylosing spondylitis indication 9631008 DOID:7147
Rheumatic heart disease indication 23685000
Atopic dermatitis indication 24079001 DOID:3310
Inflammatory bowel disease indication 24526004 DOID:0050589
Multiple sclerosis indication 24700007 DOID:2377
Severe adrenal insufficiency indication 24867002
Sarcoidosis indication 31541009 DOID:11335
Idiopathic thrombocytopenic purpura indication 32273002 DOID:8924
Psoriasis with arthropathy indication 33339001
Keloid scar indication 33659008
Crohn's disease indication 34000006
Tendinitis indication 34840004 DOID:971
Erythema multiforme indication 36715001
Contact dermatitis indication 40275004 DOID:2773
Angioedema indication 41291007 DOID:1558
Miliary tuberculosis indication 47604008 DOID:9861
Humoral hypercalcemia of malignancy indication 47709007
Articular gout indication 48440001 DOID:13189
Candidiasis of skin indication 49883006
Seborrheic dermatitis indication 50563003 DOID:8741
Edema of larynx indication 51599000
Nephrotic syndrome indication 52254009 DOID:1184
Lichen simplex chronicus indication 53891004
Systemic lupus erythematosus indication 55464009 DOID:9074
Necrobiosis lipoidica diabeticorum indication 56391002
Allergic rhinitis indication 61582004
Löffler's syndrome indication 64936001 DOID:9503
Pemphigus indication 65172003 DOID:9182
Granuloma annulare indication 65508009 DOID:3777
Tenosynovitis indication 67801009 DOID:970
Alopecia areata indication 68225006 DOID:986
Rheumatoid arthritis indication 69896004 DOID:7148
Transfusion reaction due to serum protein reaction indication 72284000
Epicondylitis indication 73583000 DOID:14087
Acquired thrombocytopenia indication 74576004 DOID:11126
Sympathetic uveitis indication 75315001 DOID:12029
Thyroiditis indication 82119001 DOID:7166
Bursitis indication 84017003 DOID:2965
Autoimmune disease indication 85828009
Congenital hypoplastic anemia indication 88854002 DOID:1339
Pruritus ani indication 90446007
Acute lymphoid leukemia indication 91857003 DOID:9952
Disorder of skin indication 95320005 DOID:37
Subacute bursitis indication 109298000
Dermatitis herpetiformis indication 111196000 DOID:8505
Hodgkin's disease indication 118599009
Non-Hodgkin's lymphoma indication 118601006
Mycosis fungoides indication 118618005
Uveitis indication 128473001 DOID:13141
Aspiration pneumonitis indication 155597006
Asthma indication 195967001 DOID:2841
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Transplanted organ rejection indication 213148006
Congenital adrenal hyperplasia indication 237751000
Scalp psoriasis indication 238608008
Adrenogenital disorder indication 267395000 DOID:0050811
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Follicular non-Hodgkin's lymphoma indication 308121000
Disorder of eye indication 371405004 DOID:5614
Primary adrenocortical insufficiency indication 373662000
Adrenal cortical hypofunction indication 386584007 DOID:10493
Erythroderma indication 399992009
Primary cutaneous T-cell lymphoma indication 400122007
Asthma management indication 406162001
Juvenile rheumatoid arthritis indication 410795001
Autoimmune hemolytic anemia indication 413603009 DOID:718
Giant cell arteritis indication 414341000 DOID:13375
Synovitis indication 416209007 DOID:2703
Aphthous ulcer of mouth indication 426965005 DOID:9663
Post traumatic osteoarthritis indication 699262001
Synovitis due to Osteoarthritis indication
Erythroblastic Anemia indication
Gingival Disorders indication
Vitrectomy Adjunct to Enhance Visualization indication
Allergic Rhinitis Prevention indication
Transfusion Reaction Urticaria indication
Systemic Dermatomyositis indication
Chronic Non-Allergic Rhinitis indication
Severe Ocular Inflammation indication
Cystic Aponeurosis Tumor indication
Diagnostic Test for Cushing's Syndrome indication
Pericarditis off-label use 3238004 DOID:1787
Chronic obstructive lung disease off-label use 13645005 DOID:3083
West syndrome off-label use 28055006
Vasculitis off-label use 31996006 DOID:865
Bronchitis off-label use 32398004 DOID:6132
Eczema off-label use 43116000
Respiratory distress syndrome in the newborn off-label use 46775006
Nasal polyp off-label use 52756005
Rheumatic fever off-label use 58718002 DOID:1586
Pseudogout off-label use 60782007
Polymyalgia rheumatica off-label use 65323003 DOID:853
Chronic hepatitis off-label use 76783007 DOID:2237
Pemphigoid off-label use 86142006
Hepatic necrosis off-label use 87248009
Multiple myeloma off-label use 109989006 DOID:9538
Polyarteritis nodosa off-label use 155441006 DOID:9810
Severe chronic obstructive pulmonary disease off-label use 313299006
Celiac disease off-label use 396331005 DOID:10608
Carditis off-label use 399617002
Neonatal Bronchopulmonary Dysplasia off-label use
Hypercalcemia associated with Sarcoidosis off-label use
Infection by Strongyloides contraindication 1214006 DOID:10955
Mycosis contraindication 3218000 DOID:1564
Ocular hypertension contraindication 4210003 DOID:9282
Gastritis contraindication 4556007 DOID:4029
Inactive tuberculosis contraindication 11999007
Epistaxis contraindication 12441001
Peptic ulcer contraindication 13200003 DOID:750
Hypercholesterolemia contraindication 13644009
Measles contraindication 14189004 DOID:8622
Disease caused by parasite contraindication 17322007
Cirrhosis of liver contraindication 19943007 DOID:5082
Arginase deficiency contraindication 23501004 DOID:9278
Glaucoma contraindication 23986001 DOID:1686
Acute tuberculosis contraindication 25629007
Fungal infection of eye contraindication 31194008
Immunosuppression contraindication 38013005
Hypertensive disorder contraindication 38341003 DOID:10763
Infectious disease contraindication 40733004
Hypothyroidism contraindication 40930008 DOID:1459
Herpes zoster keratoconjunctivitis contraindication 42448002
Hypokalemia contraindication 43339004
Chronic heart failure contraindication 48447003
Tuberculosis of eye contraindication 49107007
Cerebral malaria contraindication 53622003 DOID:14069
Tuberculosis contraindication 56717001
Congenital hyperammonemia, type I contraindication 62522004
Osteoporosis contraindication 64859006 DOID:11476
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Hypopituitarism contraindication 74728003 DOID:9406
Candidiasis of mouth contraindication 79740000 DOID:14262
Perforation of nasal septum contraindication 80142000
Hyperglycemia contraindication 80394007 DOID:4195
Open-angle glaucoma contraindication 84494001 DOID:1067
Bacterial infectious disease contraindication 87628006
Muscle atrophy contraindication 88092000 DOID:767
Herpes simplex contraindication 88594005 DOID:8566
Operation on nose contraindication 88733004
Bilateral cataracts contraindication 95722004
Seizure disorder contraindication 128613002
Disorder of muscle contraindication 129565002 DOID:423
Ophthalmic herpes simplex contraindication 186542001
Anastomosis of intestine contraindication 235407009
Disease of liver contraindication 235856003 DOID:409
Telangiectasia disorder contraindication 247479008
Edema contraindication 267038008
Pathological fracture contraindication 268029009
Diverticulitis of gastrointestinal tract contraindication 271366000
Cerebral trauma contraindication 275382005
Oral infection contraindication 275393007
Varicella-zoster virus infection contraindication 309465005
Viral eye infection contraindication 312132001
Osteopenia contraindication 312894000
Skin irritation contraindication 367466007
Herpes zoster keratitis contraindication 397573005
Avascular necrosis of bone contraindication 397758007 DOID:10159
Citrullinemia contraindication 398680004 DOID:9273
Atrophoderma contraindication 399979006
Traumatic rupture of tendon contraindication 415749005
Exposure to varicella contraindication 444453009
Periodontal Infections contraindication
Nasal Candidiasis contraindication
Untreated Fungal Infection contraindication
Oropharyngeal Candidiasis contraindication
Arginosuccinate Lyase Deficiency contraindication
Ornithine Carbamyltransferase Deficiency contraindication
Nasal Trauma contraindication
Uncontrolled Bacterial Infections contraindication
Nasal Septal Ulcers contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.2 acidic
pKa2 11.84 acidic
pKa3 13.18 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST Ki 7.59 DRUG MATRIX CHEMBL
Progesterone receptor Nuclear hormone receptor WOMBAT-PK
Annexin A1 Cytosolic other WOMBAT-PK

External reference:

IDSource
4017599 VUID
N0000145980 NUI
D00385 KEGG_DRUG
4017599 VANDF
C0040864 UMLSCUI
CHEBI:9667 CHEBI
CHEMBL1451 ChEMBL_ID
D014221 MESH_DESCRIPTOR_UI
755 INN_ID
DB00620 DRUGBANK_ID
1ZK20VI6TY UNII
31307 PUBCHEM_CID
2870 IUPHAR_LIGAND_ID
10759 RXNORM
4582 MMSL
5613 MMSL
d00620 MMSL
002188 NDDF
116594009 SNOMEDCT_US
6028009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TRIAMCINOLONE ACETONIDE Human Prescription Drug Label 1 67877-470 CREAM 0.25 mg TOPICAL ANDA 17 sections
TRIAMCINOLONE ACETONIDE Human Prescription Drug Label 1 67877-471 CREAM 1 mg TOPICAL ANDA 17 sections
TRIAMCINOLONE ACETONIDE Human Prescription Drug Label 1 67877-472 CREAM 5 mg TOPICAL ANDA 17 sections
Naltrexone HUMAN PRESCRIPTION DRUG LABEL 2 69364-3143 IMPLANT 6.50 mg SUBCUTANEOUS Unapproved drug other 25 sections